EA201891170A1 - Биомаркер поликистозной болезни почек и варианты его применения - Google Patents

Биомаркер поликистозной болезни почек и варианты его применения

Info

Publication number
EA201891170A1
EA201891170A1 EA201891170A EA201891170A EA201891170A1 EA 201891170 A1 EA201891170 A1 EA 201891170A1 EA 201891170 A EA201891170 A EA 201891170A EA 201891170 A EA201891170 A EA 201891170A EA 201891170 A1 EA201891170 A1 EA 201891170A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pkd
patient
kidney disease
polycystic kidney
biomarker
Prior art date
Application number
EA201891170A
Other languages
English (en)
Inventor
Николай Буканов
Сара Морено
Тимоти Э. Уиден
Original Assignee
Джензим Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джензим Корпорейшн filed Critical Джензим Корпорейшн
Publication of EA201891170A1 publication Critical patent/EA201891170A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

В данном документе предусмотрены способы определения эффективности средства для лечения поликистозной болезни почек (PKD) у пациента, диагностики PKD у пациента, определения стадии PKD у пациента и мониторинга PKD у пациента. Эти способы включают определение уровней AMBP один или несколько раз. Также предусмотрены наборы, которые включают антитело, которое специфически связывается с белком AMBP, и по меньшей мере одно антитело, которое специфически связывается с дополнительным маркером PKD.
EA201891170A 2015-11-18 2016-11-15 Биомаркер поликистозной болезни почек и варианты его применения EA201891170A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562257089P 2015-11-18 2015-11-18
PCT/US2016/062075 WO2017087409A1 (en) 2015-11-18 2016-11-15 Biomarker of polycystic kidney disease and uses thereof

Publications (1)

Publication Number Publication Date
EA201891170A1 true EA201891170A1 (ru) 2018-11-30

Family

ID=57539614

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891170A EA201891170A1 (ru) 2015-11-18 2016-11-15 Биомаркер поликистозной болезни почек и варианты его применения

Country Status (12)

Country Link
US (2) US11116755B2 (ru)
EP (1) EP3377908B1 (ru)
JP (1) JP6895963B2 (ru)
KR (1) KR20180083902A (ru)
CN (1) CN108700594B (ru)
AU (1) AU2016357720A1 (ru)
BR (1) BR112018009879A2 (ru)
CO (1) CO2018006126A2 (ru)
EA (1) EA201891170A1 (ru)
MX (1) MX2018006250A (ru)
WO (1) WO2017087409A1 (ru)
ZA (1) ZA201803035B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023145898A1 (ja) * 2022-01-27 2023-08-03 国立大学法人新潟大学 慢性腎臓病の尿検査方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710227B1 (en) 1998-09-16 2004-03-23 Cropdesign N.V. Cyclin-dependent kinase inhibitors and uses thereof
US6703395B2 (en) 1998-03-04 2004-03-09 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
US20040006074A1 (en) 1998-04-28 2004-01-08 The Government Of The United States Of America Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer
CA2256121A1 (en) 1998-06-08 1999-12-08 Hong Wang Cyclin-dependent kinase inhibitors as plant growth regulators
EP1086105B1 (en) 1998-06-16 2006-03-01 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Fused azepinone cyclin dependent kinase inhibitors
US6559152B2 (en) 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
DE60039601D1 (de) 1999-05-24 2008-09-04 Avi Biopharma Inc Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit
US6593356B2 (en) 1999-10-20 2003-07-15 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
AU2001253540A1 (en) 2000-04-25 2001-11-07 Bristol-Myers Squibb Company Use of 5-thio-, sulfinyl- and sulfonylpyrazolo(3,4-b)-pyridines as cyclin dependent kinase inhibitors
AU2001287157A1 (en) 2000-09-12 2002-03-26 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
AU2509602A (en) 2000-12-20 2002-07-01 Sod Conseils Rech Applic Cyclin-dependent kinase (CDK) and glycolene synthase kinase-3 (GSK-3) inhibitors
GB0101686D0 (en) 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
AU2002365211A1 (en) 2001-07-10 2003-09-02 Bristol-Myers Squibb Pharma Company 6-substituted pyrazolo (3,4-d) pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
GB0218625D0 (en) 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
NZ539162A (en) 2002-09-04 2006-07-28 Schering Corp Pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1534710B1 (en) 2002-09-04 2007-10-24 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004026229A2 (en) 2002-09-04 2004-04-01 Schering Corporation Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1545533A1 (en) 2002-09-04 2005-06-29 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MXPA05003058A (es) 2002-09-19 2005-05-27 Schering Corp Nuevas imidazopiridinas como inhibidores de cinasa dependientes de ciclina.
TWI283243B (en) 2002-09-19 2007-07-01 Schering Corp Novel pyrazolopyridines as cyclin dependent kinase inhibitors
CN1694706A (zh) 2002-09-23 2005-11-09 先灵公司 用作依赖细胞周期蛋白的激酶抑制剂的新的咪唑并吡嗪
ES2293015T3 (es) 2002-09-23 2008-03-16 Schering Corporation Imidazopirazinas como inhibidores de cinasas dependientes de ciclinas.
US7576085B2 (en) 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
WO2006012394A1 (en) 2004-07-21 2006-02-02 Tulane University Health Sciences Center Treatment of renal dysfunction and multiple myeloma using pacap compounds
EP1808694A1 (en) 2006-01-17 2007-07-18 Universitätsklinikum Freiburg Method for diagnosing polycystic kidney disease
EP2594565B1 (en) 2007-05-31 2018-10-24 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
EP2160478B1 (en) 2007-06-06 2014-08-27 Siemens Healthcare Diagnostics Inc. Predictive diagnostics for kidney disease
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
RU2578947C2 (ru) 2008-10-03 2016-03-27 Джензайм Корпорейшн Ингибиторы глюкозилцерамидсинтазы 2-ациламинопропанольного типа
WO2010141862A2 (en) 2009-06-05 2010-12-09 Mayo Foundation For Medical Education And Research Methods and materials for isolating exosomes
CN102858985A (zh) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
CN102018702B (zh) 2009-09-16 2012-07-18 北京大学 银杏内酯b的一种用途
EA201890254A3 (ru) 2009-11-27 2019-02-28 Джензим Корпорэйшн Ингибиторы глюкозилцерамидсинтазы
US20110195903A1 (en) 2009-12-15 2011-08-11 Adra Chaker N Methods and compositions for detecting recessive familial fsgs and uses thereof
US20140079769A1 (en) 2010-10-01 2014-03-20 Fabiola Terzi Methods for predicting the progression and treating a chronic kidney disease in a patient
US20130276513A1 (en) * 2010-10-14 2013-10-24 The Regents Of The University Of California Methods for diagnosing and assessing kidney disease
JP6021021B2 (ja) 2010-11-05 2016-11-02 国立大学法人京都大学 多発性嚢胞腎の検査方法および治療剤のスクリーニング方法
JP2015527870A (ja) 2011-10-03 2015-09-24 セルマティックス， インコーポレイテッド 推定出生児が状態を発症する危険性を評価するための方法およびデバイス
US8961959B2 (en) 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
CN102590491B (zh) * 2012-02-06 2014-12-10 中国人民解放军第三军医大学第一附属医院 一种用于早期筛查或辅助诊断泌尿系统疾病的检测试剂盒、检测方法及其用途
WO2014006093A1 (en) 2012-07-03 2014-01-09 Boletta Alessandra Compounds for use in polycystic kidney disease
JOP20130273B1 (ar) * 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
MX2017001648A (es) 2014-08-04 2017-04-27 Genzyme Corp Biomarcadores de enfermedad poliquistica renal y usos de los mismos.

Also Published As

Publication number Publication date
CN108700594A (zh) 2018-10-23
US11116755B2 (en) 2021-09-14
WO2017087409A1 (en) 2017-05-26
AU2016357720A1 (en) 2018-07-05
CO2018006126A2 (es) 2018-07-10
ZA201803035B (en) 2019-02-27
CN108700594B (zh) 2021-06-29
US20210379031A1 (en) 2021-12-09
EP3377908B1 (en) 2020-08-05
JP2019502902A (ja) 2019-01-31
BR112018009879A2 (pt) 2018-11-13
US20180338961A1 (en) 2018-11-29
MX2018006250A (es) 2018-09-05
JP6895963B2 (ja) 2021-06-30
KR20180083902A (ko) 2018-07-23
EP3377908A1 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
EA201791578A1 (ru) Панель биомаркеров для обнаружения рака
EA201792679A1 (ru) Способы диагностики и лечения злокачественной опухоли
EA201500835A1 (ru) Терапевтическая и диагностическая мишень для рака, включающая dll3-связывающие реагенты
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
BR112017010137A2 (pt) polipeptídios fixadores de pd-l1 para imagem
MX2020001193A (es) Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos.
DK2885641T3 (da) Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension
WO2015176066A3 (en) Lpa-associated protein and rna expression
BR112016018205A2 (pt) métodos de tratamento de mal de alzheimer
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
EA201790211A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака
EA201990730A1 (ru) Рнк-биомаркеры для наследственного ангионевротического отека
BR112018008799A2 (pt) método de prognóstico
BR112019005167A2 (pt) método e kit para analisar uma amostra
EA201792669A1 (ru) Igfbp3 и его применение
MX2019003569A (es) Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos.
EA201890739A1 (ru) Анти-s100a8 для лечения лейкемии
NZ729773A (en) Biomarkers for disease progression in melanoma
WO2015168602A3 (en) Methods and compositions for the diagnosis and treatment of kawasaki disease
GB2552271A (en) A method for diagnosing lung cancer
WO2016198833A3 (en) Methods for analysing a urine sample
EA201990720A1 (ru) Способы детекции нейтрализующих антител к лептину
BR112016017926A2 (pt) ensaio para detectar periostina humana